Sylvain D.
- Country
- France
- Department
- Radiotherapy / Oncology
Research Overview
- Evaluation of Darolutamide Combined with Stereotactic Body Radiation Therapy in Castration-Resistant Prostate Cancer with Oligometastases Detected by Functional Imaging
- (21492 ARASTEP) A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical recurrence (BCR) of prostate cancer
Data & Insights
Has run more than one trial at 11 of 158 partner sites.
Specializations
Prostate Cancer Research
This investigator specializes in studying biochemically recurrent prostate cancer, with particular focus on developing therapeutic approaches for patients showing elevated PSA (Prostate Specific Antigen) levels.
- Hormone Therapy Applications
- Prostate Cancer Biomarkers
- Disease Recurrence Patterns
The investigator's work encompasses evaluation of androgen deprivation therapy (ADT) combinations and their impact on disease progression.
Diagnostic Imaging
The investigator utilizes advanced imaging techniques including PSMA PET/CT scanning for monitoring treatment response and disease progression in prostate cancer patients.
- Molecular Imaging Technologies
- Treatment Response Assessment
- Disease Monitoring Protocols
Their expertise includes implementing imaging-based approaches for evaluating therapeutic effectiveness in oncology.
Therapeutic Development
The investigator focuses on evaluating novel therapeutic combinations for high-risk prostate cancer patients, particularly those showing biochemical recurrence.
- Treatment Duration Optimization
- Combination Therapy Approaches
- Risk Assessment Strategies
Their research interests include investigating treatment duration parameters and therapeutic combinations for optimal patient outcomes.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.